CXCR4 Expression in Prostate Cancer Progenitor Cells by Dubrovska, Anna et al.
CXCR4 Expression in Prostate Cancer Progenitor Cells
Anna Dubrovska
1*
¤c, Jimmy Elliott
2, Richard J. Salamone
2, Gennady D. Telegeev
4, Alexander E.
Stakhovsky
3, Ihor B. Schepotin
3, Feng Yan
2, Yan Wang
2, Laure C. Bouchez
1¤b, Sumith A. Kularatne
1,
James Watson
2, Christopher Trussell
2, Venkateshwar A. Reddy
1,2¤a, Charles Y. Cho
2, Peter G. Schultz
1*
1The Scripps Research Institute, La Jolla, California, United States of America, 2Genomics Institute of the Novartis Research Foundation, San Diego, California, United
States of America, 3National Cancer Institute, Kyiv, Ukraine, 4Institute of Molecular Biology and Genetics NAS of Ukraine, Kyiv, Ukraine
Abstract
Tumor progenitor cells represent a population of drug-resistant cells that can survive conventional chemotherapy and lead
to tumor relapse. However, little is known of the role of tumor progenitors in prostate cancer metastasis. The studies
reported herein show that the CXCR4/CXCL12 axis, a key regulator of tumor dissemination, plays a role in the maintenance
of prostate cancer stem-like cells. The CXCL4/CXCR12 pathway is activated in the CD44
+/CD133
+ prostate progenitor
population and affects differentiation potential, cell adhesion, clonal growth and tumorigenicity. Furthermore, prostate
tumor xenograft studies in mice showed that a combination of the CXCR4 receptor antagonist AMD3100, which targets
prostate cancer stem-like cells, and the conventional chemotherapeutic drug Taxotere, which targets the bulk tumor, is
significantly more effective in eradicating tumors as compared to monotherapy.
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Introduction
Prostate cancers are the second most common cause of cancer
death in men. Most prostate cancers are hormone dependent and
respond to androgen ablation therapy. However, ablation therapy
is not curative for metastatic prostate cancers, because these
tumors eventually become hormone refractory and grow despite
androgen ablation, even though initial treatment appeared
successful [1], [2]. Chemotherapy regimens that include the drug
docetaxel (Taxotere) extend median survival by two to three
months in patients with advanced prostate cancer that is no longer
responsive to hormone therapy. Nevertheless, with a 5 year
survival rate of 17% patients and a median survival period of 2–3
years, the prognosis for patients with metastatic prostate cancer
remains poor [3].
It has been argued that tumor progenitor cells play a crucial role
in tumor development and represent a drug resistant cell population
that can survive conventional treatment and cause disease relapse
[4]. This notion suggests that therapies targeting tumor progenitors
may lead to more effective cancer treatments [5], [6]. Cell
populations expressing the surface markers CD133 and CD44
have been identified as putative stem cell populations in the prostate
gland [5], [7], [8], [9]. We and others have demonstrated that
CD133
+/CD44
+ cells from established prostate cancer cell lines are
also self-renewing and multipotent, and have strong tumorigenic
potential in vivo [5], [7], [10], [11], [12]. Whereas prostate cancer
cell lines cultured under long-term monolayer culture conditions
contain less than 2% prostate cancer progenitors, this CD133
+/
CD44
+ cancer progenitor population can be expanded under
anchorage independent serum-free conditions (sphere forming
conditions)[5],[11].Thisenrichedprogenitorpopulationmaintains
increased self-renewal capacity and tumorigenicity [5]. mRNA
expression analysis revealed that the chemokine receptor CXCR4 is
highly upregulated in these cells compared to cells cultured under
monolayer growth conditions [5]. It is known that activation of the
CXCR4/CXCL12 pathway alters the adherence, migration, and
invasion of cancer cells, including prostate cancer [13], [14], [15].
However, little is known about the role of this pathway in the
maintenance of prostate tumor initiating cell populations. Herein
we report studies that suggest the CXCR4/CXCL12 axis is
activated in prostate cancer progenitors and plays a role in self-
renewal, differentiation potential, cell adhesion, and tumorigenicity.
Moreover, mouse xenograft studies suggest that inhibition of the
CXCR4 pathway may be beneficial in the targeting of prostate
cancer progenitors in vivo.
Results
The CXCL4/CXCR12pathway is activated in the CD44
+/
CD133
+prostate progenitor population
Several putative stem cell populations have been identified in
prostate and are characterized by the cell surface markers CD44,
CD133, and integrin a2b1
high [5], [7], [8], [9], [10], [11], [12].
Prostate cancer cells expressing CD44 and CD133 cell surface
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,markers can be enriched from prostate cancer cell lines by growing
them as spheres in progenitor media conditions [5]. We and others
have confirmed that this CD133
+/CD44
+ cell population makes
up a subset of prostate cancer cells that are self renewing,
differentiate into heterogeneous tumors, and are highly tumori-
genic in immunodeficient mice [5], [7], [8], [9], [10], [11], [12].
To identify signaling pathways selectively activated in this
CD133
+/CD44
+ population, we carried out microarray analysis
of gene expression in DU145 and PC3 cells using Affymetrix U133
arrays [5]. Gene expression profiling showed that the chemokine
receptor CXCR4 is highly upregulated in both cell lines grown
under sphere forming compared to monolayer growth conditions
(a 13-fold increase and 104.6-fold increase for PC3 and DU145
cells, respectively) [5]. The high level of CXCR4 expression
observed in microarray experiments was confirmed by quantita-
tive RT-PCR and Western blot analysis (Figure 1A).
A growing body of evidence has demonstrated that CXCR4
plays an important role in cancer proliferation, dissemination,
invasion and drug resistance [13], [14], [15], [16], [17], [18], [19],
[20], [21], [22]. However, little is known about the role of the
Figure 1. Overexpression of CXCR4 inprostate cancer progenitors. (A) Cells grown under sphere forming conditions showed an increased
expression level of CXCR4 as analyzed by RT-PCR and Western blot analysis. For sphere formation, single cells were plated at 500 cells/mL in 10-cm
dishes with an ultralow attachment surface and grown in serum-free epithelial basal medium for 7 days. (B) Flow cytometry analysis showed
significant enrichment of the CXCR4
+ population within CD44
+/CD133
+ cells compared to the total cell population for DU145 and PC3 cells
(p,0.001). The cells were triple stained and analyzed with a BD LSR II flow cytometer. (C) Representative fluorescent images of CD133 and CD44 co-
immunostaining showing that CXCR4
+ DU145 and PC3 cells have a higher proportion of CD44
+/CD133
+ cells compared to CXCR4
2 cells. Cells
expressing high of low levels of CXCR4 were FACS-purified, plated in 384 well black clear bottom plates at a density of 100 cells/well in serum-free
epithelial basal medium. After 18 hours, the cells were fixed with 3.7% formaldehyde in PBS and stained with anti-CD133 and anti-CD44 antibodies.
Cells in at least five randomly selected fields of view were counted for each condition. Arrows show the triple positive cells. Scale bars indicate 15 mm.
*- p value,0.05. (D) Immunostaining of paraffin-embedded sections of xenograft tumors formed by FACS purified CD44
+/CD133
+ and CD44
2/
CD133
2 cells showed more than 13% CXCR4
+ cells in tumors derived from CD44
+/CD133
+ cells compared to 2.2% CXCR4
+ cells in xenograft tumors
derived from CD44
2/CD133
2 cells. A total of 10
3 FACS-sorted DU145 CD133
+/CD44
+ or CD133
2/CD44
2 cells embedded in BD matrigel were injected
s.c. into NOD/SCID mice. Tumors were allowed to grow for 42 days until the tumors produced by DU145 CD133
+/CD44
+ reached a size of 400 mm
3
and the tumors produced by DU145 CD133
2/CD44
2 reached a size of 125 mm
3. Cells in at least five randomly selected fields of view were counted
for each condition. Scale bars indicate 30 mm. (E) CXCR4 immunostaining on paraffin-embedded sections of xenograft tumors made by the cells
grown under sphere forming and monolayer conditions showed more than 6% CXCR4
+ cells in sphere-derived tumors as compared to 1.4% of
CXCR4
+ cells in monolayer-derived xenograft tumors. **- p value,0.01.Scale bars indicate 30 mm.
doi:10.1371/journal.pone.0031226.g001
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prostate cancer progenitors. To verify that CXCR4 expression is
upregulated in prostate tumor initiating cells, we examined
CXCR4 levels in CD44
+/CD133
+ prostate cancer progenitor
cells and total cell populations in the DU145 and PC3 cell lines by
flow cytometry. We observed a 10.3- and 2.3-fold enrichment in
the percentage of CXCR4
+ cells in the CD44
+/CD133
+
population compared to the percentage of CXCR4
+ cells in the
total population of DU145 and PC3 cells, respectively (Figure 1B).
Consistent with this observation, FACS-purified DU145 CXCR4
+
and PC3 CXCR4
+ populations have a considerably higher
proportion of CD133
+/CD44
+ cells as compared to CXCR4
2
cells (a 5.8-fold and 2.8-fold increase for DU145 and PC3 cells,
respectively) (Figure 1C). This increased level of CXCR4
expression in the CD133
+/CD44
+ cell population suggests an
important role for CXCR4 signaling in the maintenance of
prostate cancer progenitors.
To determine whether the same correlation exists in vivo we
analyzed CXCR4 expression in tumors from mice injected with
CD133
+/CD44
+ enriched cells as well as cells grown under sphere
forming conditions. Both prostate cell populations have previously
been shown to have increased tumorigenicity [5], [12]. Histolog-
ical analysis of DU145 xenograft tumors derived from FACS-
purified CD44
+/CD133
+ cells revealed a significantly higher
CXCR4
+ cell population than in tumors formed by CD44
2/
CD133
2 cells (Figure 1D). Similarly, analysis of CXCR4
expression in xenograft tumors from mice injected with DU145
cells grown under sphere or monolayer conditions showed that
CXCR4 expressing cells make up 6.1% of the total cell population
in sphere-derived tumors, whereas monolayer-derived tumors
have 1.4% of CXCR4 positive cells (Figure 1E). Thus, a higher
percentage of cells expressing CXCR4 is also associated with
tumors derived from both CD44
+/CD133
+ cells or cells grown
under sphere forming conditions.
Next, we analyzed the relationship between CXCR4 expression
and the self renewal capacity and tumorigenicity of prostate cancer
progenitor cells. Both FACS sorted DU145 and PC3 CXCR4
+
populations showed an increase in sphere and colony forming
potential over CXCR4
2 cells (2.3-fold increase and 3.9-fold
increase, respectively) (Figure 2A, B). Similarly, CD44
+/CD133
+/
CXCR4
+ cells have higher spherogenic potential as compared to
CD44
+/CD133
+/CXCR4
2 cells (Figure 2C). To evaluate the self-
renewal capacity of CXCR4
+ cells, secondary spheres were
generated from dissociated primary spheres derived from PC3
CXCR4
+ and PC3 CXCR4
2 cells (Figure S1A). The number of
secondary spheres per 1000 or 500 cells was higher with spheres
derived from CXCR4
+ cells than from CXCR4
2 cells (a 5.5-fold
increase and 3.2-fold increase, respectively). To determine
whether activation of the CXCR4/CXCL12 axis stimulates
proliferation of prostate cancer progenitors, PC3 and DU145
cells were treated with CXCL12 at 10 and 100 ng/mL for 5 days
in serum-free epithelial growth medium. As shown in Figure 2D,
activation of the CXCR4/CXCL12 signaling pathway signifi-
cantly increases the CD44
+/CD133
+ population for both PC3 and
DU145 prostate cancer cell lines in a dose dependent manner (up
to 3.5-fold and 2.6-fold increase, respectively). Similarly, adeno-
virus-mediated overexpression of CXCR4 in DU145 cells resulted
in a more than 2.5-fold increase of the CD44
+/CD133
+
population (Figure 2E and Figure S1B), but had little effect on
the CD44
2/CD133
2 and total cell populations. To further
characterize the tumor forming potential of CXCR4
+ cells, 1000
FACS-purified CXCR4
+ and CXCR4
2DU145 cells were injected
subcutaneously into NOD/SCID mice. CXCR4
+ cells were found
to have significantly higher tumorigenicity than CXCR4
2 cells (up
to 3.8-fold increase in xenograft tumor growth, Figure 2F, Figure
S1C). In fact the CD44
+/CD133
+ and CXCR4
+ cells exhibited a
similar tumorigenic potential in vivo. These results indicate that
expression of CXCR4 contributes to tumorigenic potential of
androgen refractory prostate cancer cell lines.
Finally, we determined whether CXCR4
+ and CXCR4
2 cells
exhibit distinct differentiation potential by analyzing these cell
populations for expression of prostate lineage markers. Previous
studies demonstrated that prostate cancer can originate from
CK5
+ basal cells with multilineage differentiation potential [23],
[24]. DU145 and PC3 cells were sorted into the CXCR4
+ and
CXCR
2 fractions and grown on tissue culture treated plastic
under differentiation conditions. Interestingly, CXCR4
+ popula-
tions in DU145 and PC3 cell lines are more heterogeneous as
compared to CXCR4
2 cells and include a CK5
+ population of
basal epithelial cells, intermediate population of basal-like CK5
+/
CK18
+ cells, and CK18
+ population of luminal epithelial cells. In
contrast, CXCR4
2 cells differentiate to CK5
2/CK18
+ and
CK5
+/CK18
+ cells but do not give rise to CK5
+ basal epithelial
cells (Figure 3). This result suggests that the CXCR4
+ population
harbors more tumorigenic basal-like cells, which is consistent with
recent findings that basal epithelial cells are a cell of origin for
prostate cancer [25].
CXCR4/CXCL12 pathway regulates prostate cancer cells
through a PI3K/AKT/FOXO3A dependent feedback loop
Recently we showed that activation of the PI3K/AKT pathway
is important for prostate cancer progenitor self-renewal and
tumorigenicity [5], [12]. Moreover, a previous study demonstrated
that the CXCR4/CXCL12 interaction activates PI3K/AKT
signaling in prostate cancer cells [26]. Thus CXCR4 may
contribute to maintenance of prostate cancer progenitors through
activation of the PI3K/AKT axis. PI3K/AKT signaling regulates
transcription through the forkhead family of transcription factors
(FOXO) by phosphorylating conserved serine/threonine residues.
Transcriptionally active FOXOs affect a wide range of biological
processes, including cell survival, DNA repair, oxidative stress
response, and longevity [27]. Among the members of the FOXO
family, FOXO3A has been shown to be important for the
maintenance of neural, hematopoietic, and endothelial stem cells
[28], [29], [30], and prostate cancer stem-like cell populations [5],
[12]. Consistent with earlier experiments which showed that
FOXO3a-dependent gene expression is inhibited in the CD44
+/
CD133
+ prostate cancer progenitors versus CD44
2/CD133
2 cells
[5], we found that the FACS purified CXCR4
+ PC3 cell
population showed decreased expression levels of FOXO3A
responsive genes such as p21, GADD45, p130, BIM1, and
CyclinG2 compared to CXCR4
2 cells, suggesting that increased
expression of CXCR4 is associated with PI3K activation
(Figure 4A). Treatment of prostate cancer cells with CXCL12 at
a concentration of 100 ng/ml induced activation of the PI3K/
AKT pathway (up to 1.5–2.0 fold increase in AKT phosphory-
lation in PC3 and DU145 cells, respectively) (Figure 4B), in
addition to increasing the CD44
+/CD133
+ population for both
PC3 and DU145 cells (Figure 2D). Conversely, the PI3K
inhibition completely abolished the effect of CXCL12 on the
proliferation of CD44
+/CD133
+ progenitors (Figure 4C), and
reduced the level of CXCR4 expression in both DU145 and PC3
cells in vitro and in vivo (Figure 4D, E).
We also observed a decrease in CXCR4 protein levels in
response to FOXO3A overexpression in DU145 cells (Figure 4F)
suggesting that FOXO3A could regulate CXCR4 levels directly
through CXCR4 transcriptional regulation or indirectly via a
different FOXO3A target gene. Inspection of the CXCR4
CXCR4 Expression in Prostate Cancer Progenitors
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GCAAACA [32] from positions 2187 to 2181. In order to
confirm that FOXO3A binds to the CXCR4 promoter, a
chromatin immunoprecipitation assay (ChIP) was performed.
The amount of precipitated CXCR4 promoter was increased in
DU145 cells stably transfected with FOXO3A-GFP protein
(Figure 4G) demonstrating that FOXO3A binds to CXCR4
promoter. These data show a relationship between PI3K/AKT
signaling activation, CXCR4 expression and the self renewal
capacity and tumorigenicity of CD44
+/CD133
+ prostate cancer
progenitor cells.
CXCR4 regulates tumor progenitor cell adhesion
The role of CXCR4 in cancer progression has generally been
analyzed in the context of cancer cell metastasis [19], [20], [21],
[22], [33]. At the molecular level, CXCR4 is an important
mediator of the interaction of prostate tumor cells with
extracellular matrix proteins such as laminin, fibronectin, and
collagen which contributes to the metastatic process [14], [34],
[35]. Despite the fact that CXCR4 does not directly modulate cell
attachment, CXCR4 receptor engagement by CXCL12 plays an
essential role in managing cell adhesion by modulation of integrin
expression, FAK phosphorylation, and activation of p38 MAPK
and ROCK kinases [34], [36]. To examine the role of CXCR4 in
the cell adhesion and migration of prostate tumor initiating cells,
we compared FACS sorted CD44
+/CD133
+/CXCR4
+ cells with
other populations in cell adhesion assays. We found that CD44
+/
CD133
+/CXCR4
+ cells have significantly higher CXCL12-
dependent adhesion to fibronectin than CD44
+/CD133
+/
CXCR4
2 or CD44
2/CD133
2/CXCR4
2 cells populations
(Figure 5A). The CXCL12-induced adhesion of prostate cancer
cells to the extracellular matrix is mediated by integrins.
Interestingly, the expression levels of a2, a5, and b3 integrin
subunits are strongly upregulated in CD133
+/CD44
+ DU145
compared to CD133
2/CD44
2 DU145 cells (Figure 5B), consis-
tent with recent studies which show that activation of the
CXCR4/CXCL12 pathway in DU145 cells leads to enhanced
expression of a5 and b3 integrins [14]. Additionally, inactivation
of the PI3K pathway with NVP-BEZ235 (200 nM) significantly
decreased CXCR4-dependent adhesion of CD133
+/CD44
+
DU145 cells to fibronectin, and this inhibition could be abolished
in the presence of 200 ng/mL CXCL12 (Figure 5C). Remarkably,
adhesion of CD133
2/CD44
2 DU145 cells did not respond to
CXCL12 treatment or PI3K signaling inhibition (Figure 5C).
Collectively, these studies suggest that expression of CXCR4 could
provide a selective advantage for interaction with the extracellular
Figure 2. CXCR4/CXCL12 signaling pathway plays an important role in the maintenance of prostate cancer progenitor cells. CXCR4
+
DU145 and PC3 cells showed an increase in (A) clonogenicity and (B) sphere forming ability over CXCR4
2 cells. (C) CD44
+/CD133
+/CXCR4
+ DU145 cells
showed an increase in sphere forming ability compared to CD44
+/CD133
+/CXCR4
2 cells. The cells were purified by FACS and plated in 24-well low
attachment plate at a density of 100 cells/well in serum-free epithelial basal medium and grown for 10 days. **- p value,0.01. (D) Flow cytometry
analysis showed that CXCL12 stimulates proliferation of prostate cancer progenitors in DU145 and PC3 cell lines in a dose-dependent manner. DU145
and PC3 cells were grown in serum-free, EBM medium with supplements and treated with the indicated concentrations of CXCL12 replenished daily
for 5 days. (E) Overexpression of CXCR4 in prostate cancer cells resulted in a 3-fold increase of CD44
+/CD133
+ population. DU145 cells were infected
with adenovirus encoding CXCR4 under the control of the tet-off regulatory system, and with control adenovirus and analyzed 4 days after infection.
CXCR4 expression was validated by flow cytometry analysis. (F) CXCR4
+ cells possess higher tumorigenic properties compared to CXCR4
2 cells. 10
3
CXCR4
+, CXCR4
2, CD44
+/CD133
+ and CD44
2/CD133
2 DU145 cells collected by FACS sorting were embedded in BD matrigel and injected s.c. into
NOD/SCID mice. Each experimental group contained at least five mice. Error bars represent SEM.
doi:10.1371/journal.pone.0031226.g002
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+ populations in DU145 and PC3 cell lines are multipotent. FACS purified CXCR4
+ and CXCR4
2 DU145 and PC3 cells were
cultured under differentiation conditions in the presence of 10% FBS.CXCR4
+ cells differentiate toCK5
+ basal epithelial cells (10.7%), CK5
+/CK18
+
intermediate cells (32.2%), and CK18
+ luminal epithelial cells (57.1%). In contrast, CXCR4
2 cells differentiate to CK18
+cells (91.9% of total cell
population) and CK5
+/CK18
+ cells (8% of total cell population) but not basal epithelial cells. Scale bars indicate 15 mm.
doi:10.1371/journal.pone.0031226.g003
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cells allowing further tumor dissemination.
Inhibition of the CXCR4 pathway leads to a decrease in
prostate cancer progenitor populations
To provide additional evidence that the CXCR4/CXCL12
signaling is important for stem-like cell maintenance and targeting
of this pathway can lead to inhibition of prostate cancer progenitor
growth, we tested if inactivation of the CXCR4/CXCL12 axis by
a neutralizing antibody affects prostate cancer progenitors in vitro
and in vivo. DU145 cells were treated with 10 mg/mL neutralizing
anti-CXCR4 (mouse monoclonal IgG, clone 44716, R&D
Systems) or control antibody (mouse IgG isotype control, Lifespan
Bioscience Inc.) for 5 days in serum-free epithelial growth medium
and sphere forming ability was measured. Treatment with anti-
CXCR4 antibody leads to a 2.2-fold decrease in sphere forming
ability in DU145 cells compared to cells treated with control
antibody (Figure 6A). Furthermore, flow cytometry analysis
revealed a more than 2-fold decrease in the CD44
+/CD133
+
population in DU145 cells pretreated with anti-CXCR4 antibody
(Figure 6B) as well as inhibition of the PI3K/AKT1 signaling
pathway (Figure 6C). Preincubation of DU145 cells with anti-
Figure 4. The PI3K pathway mediates the function of CXCR4 in prostate tumor initiating population. (A) Isolated CXCR4
+ PC3 cells
showed decreased expression levels of FOXO3A responsive genes such as p21, GADD45, p130, BIM1, CyclinG2 compared to CXCR4
2PC3 cells. mRNA
levels were determined by quantitative RT-PCR and normalized to GAPDH mRNA. (B) Treatment of prostate cancer cells with CXCL12 induced
activation of the PI3K/AKT pathway. DU145 and PC3 cells were grown in serum-free, EBM medium with supplements and treated with the indicated
concentrations of CXCL12 and NVP-BEZ235 for 18 hours. (C) Proliferative effect of CXCR4/CXCL12 signaling on CD44
+/CD133
+ progenitors could be
completely abolished by PI3K inhibition. DU145 and PC3 cells were grown in serum-free, EBM medium with supplements and treated with the
indicated concentrations of CXCL12 and NVP-BEZ235 replenished daily for 5 days. (D) Treatment of DU145 and PC3 cells with PI3K inhibitors
LY294002 and NVP-BEZ235 reduced the level of CXCR4. (E) PI3K inhibition decreases CXCR4 expression in vivo. DU145 cells were injected
subcutaneously into NOD/SCID mice. When the tumors had grown to a size of 300 mm
3, the mice were treated with NVP-BEZ235 (12.5 mg/kg given
every day perorally) or with vehicle for 5 weeks. Histological analysis of paraffin embedded sections demonstrates reduction of CXCR4 expression in
xenograft tumors treated with the PI3K inhibitor. Scale bars indicate 15 mm. (F) DU145 cells stably transfected with FOXO3A-GFP have decreased
CXCR4 expression. Western blot analysis shows endogenous and overexpressed FOXO3A fusion proteins (arrows). (G) ChIP assay demonstrates that
FOXO3A binds to the CXCR4 promoter. DU145 and PC3 cells were stably transfected with either GFP or FOXO3A-GFP as described [17]. Cells were
crosslinked with formaldehyde and chromatin was immunoprecipitated with anti-FOXO3A/FKHRL1 antibody. The crosslinked genomic CXCR4
promoter was detected by PCR. FOXO3a regulated gene eNOS was used as a positive control. The amount of precipitated FOXO3A-CXCR4 promoter
was increased in DU145 cells stably transfected with FOXO3A-GFP protein.
doi:10.1371/journal.pone.0031226.g004
CXCR4 Expression in Prostate Cancer Progenitors
PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31226CXCR4 antibody before subcutaneous injection into NOD/SCID
mice significantly delayed tumor growth (Figure 6D), compared to
cells treated with control antibody.
We then tested the effects of the CXCR4-specific small
molecule antagonist AMD3100 on the survival of the progenitor
population (CD44
+/CD133
+) within prostate cancer cell lines.
PC3 cells were treated with 0.5 mM AMD3100 or with 75 mM
of the conventional chemotherapeutic drug 5-fluorouracil for 4
days in serum-free epithelial growth medium. Flow cytometry
analysis revealed a 2.2-fold decrease in the CD44
+/CD133
+
population with AMD3100 treatment (Figure 7A and Figure
S2A), whereas this population was increased up to 2.1 fold in
response to conventional therapy. In contrast, the CD44
2/
CD133
2 population was sensitive to conventional chemother-
apy showing a 2.1-fold decrease, but was unresponsive to
AMD3100 treatment. Additionally, the combination of
AMD3100 and the chemotherapeutic drug resulted in a
simultaneous decrease of both CD44
+/CD133
+ and CD44
2/
CD133
2 cell populations ($1.8-fold decrease and 1.7-fold
decrease respectively).
Combination therapy targeting progenitor and bulk
tumor cells leads to enhanced tumor regression
To determine whether the in vitro effect seen with the
combination of AMD3100 and 5-fluorouracilcan be recapitulated
in vivo, DU145 hormone-refractory prostate carcinoma xenograft
tumors were treated with a combination of the AMD3100 and the
cytotoxic antimicrotubule agent Taxotere. 500,000 DU145 cells
were injected subcutaneously into NOD/SCID mice. When the
tumors had grown to a size of 300 mm
3, the mice were treated
Figure 5. CXCR4 regulates tumor progenitor cell adhesion. (A) DU145 CD44
+/CD133
+/CXCR4
+ cells have significantly higher CXCL12-
dependent adhesion to fibronectin than CD44
+/CD133
+/CXCR4
2 or CD44
2/CD133
2/CXCR4
2 cells populations. Cells were FACS sorted and plated on
fibronectin coated plates and allowed to adhere for 1 h. The cells were counted in three wells per condition using a phase-contrast microscope.*-p
value,0.05. (B) The expression level of a2, a5, and b3 integrins subunits is strongly upregulated in CD133
+/CD44
+ DU45 compared to CD133
2/CD44
2
DU45 cells. (C) Inactivation of the PI3K pathway with NVP-BEZ235 significantly decreases CXCR4-dependent adhesion of CD133
+/CD44
+ DU45 cells to
fibronectin. The adhesion of CD133
+/CD44
+ DU45 cells could be restored in the presence of CXCL12. The adhesion of CD133
2/CD44
2 DU45 did not
respond to the CXCR4 and PI3K signaling modulation, *-p value,0.05.
doi:10.1371/journal.pone.0031226.g005
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AMD3100 (given in subcutaneous osmotic pumps loaded with
20 mg/mL AMD3100 with an infusion rate 0.5 ml/h), or the
combination. After 25 days, the xenograft tumors treated with
AMD3100 or Taxotere alone showed a decrease in tumor growth
rate compared to the control group (a 1.8-fold decrease and 8-fold
decrease, respectively) (Figure 7B). The combination treatment, on
the other hand, led to a 20-fold difference in tumor size relative to
the control, starting at week two. Histological analysis revealed
more than 2-fold attenuation of the CD44
+/CD133
+ population
in the xenograft tumors treated with AMD3100, alone or in
combination with Taxotere. In contrast, the CD44
+/CD133
+
population was increased after Taxotere monotherapy (Figure 7C
and Figure S2B). Western blot analysis showed a decrease in
FOXO3A phosphorylation in tumors treated with AMD3100
alone, suggesting that enhanced tumor regression upon treatment
with AMD3100 is mediated by inhibition of the PTEN/PI3K/
AKT pathway (Figure 7D). We observed that the tumors treated
with both Taxotere and NVP-BEZ235 showed slower regrowth
during the 10 days after the treatment was terminated as
compared with tumors treated with Taxotere alone (a 2.3-fold
increase and 2.9-fold increase, respectively) (Figure 7B). The
endpoint tumors treated with combination therapy were still a
modest 210 mm
3 on average compared to nearly 480 mm
3 for
Taxotere alone suggesting that treatment with CXCR4 antago-
nists directed against progenitor cells may be useful in combina-
tion with conventional drugs in prostate cancer treatment. Taken
together, these studies suggest that targeting the CXCR4/
CXCL12 pathway results in decreased prostate progenitor survival
in vitro and in vivo in androgen refractory cancer cell lines and
potentially could be of therapeutic value against advanced prostate
cancers.
Figure 6. CXCR4 neutralization leads to attenuation of the CD44
+/CD133
+ prostate progenitor population. (A) DU145 cells were plated
in 96-well low-attachment plates at 100 cells per well (5 replicates) and the spheres were grown in serum-free, EBM medium with supplements. The
antibodies were replenished daily. Cells were imaged with an Acumen eX3 microplate cytometer and spheres were detected using image analysis
software. The sphere size was measured by GFP intensity. The spheres were discriminated from cell debris using a Gaussian filter. The spheres
included in the analysis are outlined in red and indicated by arrows. Representative data from one of two independent experiments is shown; *- p
value,0.05. (B) Flow cytometry analysis revealed attenuation of CD44
+/CD133
+ population in DU145 cells treated with 10 mg/ml neutralizing anti-
CXCR4 (mouse monoclonal IgG, clone 44716, R&D Systems) or 10 mg/ml control antibody (mouse IgG isotype control, Lifespan Bioscience Inc.) for 5
days. The cell were grown in medium supplemented with 2% FBS. Culture medium was refreshed every second day; *- p value,0.05. (C) Western blot
analysis of DU145 cells treated with 10 mg/ml neutralizing anti-CXCR4 antibody for 5 days demonstrated downregulation of the PI3K/AKT pathway
activation compared to the cells treated with 10 mg/ml control antibody. The cell were grown in medium supplemented with 2% FBS. Culture
medium was refreshed every second day. (D) Preincubation of prostate cancer cells with neutralizing anti-CXCR4 antibody significantly delays tumor
growth. 5610
5 DU145 cells pretreated with neutralizing anti-CXCR4 or control antibody for 5 days were embedded in BD matrigel and injected s.c.
into NOD/SCID mice.*- p value,0.01.
doi:10.1371/journal.pone.0031226.g006
CXCR4 Expression in Prostate Cancer Progenitors
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e31226Discussion
A growing body of evidence has demonstrated that many
human tumors contain a heterogeneous mixture of different cell
types and are maintained by subpopulations of tumor progenitors
[4]. Tumor progenitor cells can divide symmetrically to self-renew
and asymmetrically to differentiate into heterogeneous tumors and
cause tumor formation and subsequent metastasis. Prostate cancer
progenitor populations can be defined by the expression of cell
surface markers CD44, CD133, and a2b1
high integrin [5], [7], [8],
[9], [10], [11], [12]. Whereas prostate cancer cell lines have less
than a 2% progenitor population when cultured under long-term
monolayer culture conditions, prostate cancer progenitor popula-
tions expressing CD44 and CD133 cell surface markers can be
significantly enriched when grown under sphere-forming condi-
tions [5], [11]. Effective targeting of the tumor initiating cell
population requires a detailed understanding of the cellular
pathways that contribute to maintenance of stemness. To better
understand self-renewal pathways in prostate cancer progenitors,
we performed gene expression profiling and found that CXCR4 is
highly expressed in prostate cancer cells grown as spheres. This
was an intriguing finding because of CXCR4’s well-known role in
tumor metastasis. While the role of CXCR4 has been examined in
the cancer stem cell context in pancreatic cancer [33], character-
ization of CXCR4 signaling in prostate cancer progenitors has not
been reported.
We confirmed increased expression of CXCR4 in prostate cancer
cells grown under sphere forming conditions compared to
monolayer conditions, and in CD44
+/CD133
+ prostate tumor
initiating cells compared to CD44
2/CD133
2 cells. Further, the
relationship between CXCR4 and tumor initiating cell markers
CD133/CD44 is reciprocal: CXCR4
+ cells have a higher
percentage of CD133
+/CD44
+ than CXCR4
2 cells and CD133
+/
CD44
+ cells contain more CXCR4
+ cells than CD133
2/CD44
2
cells. This finding implies that in prostate tumor initiating cells,
CXCR4 isimportant for the maintenance of stemness. In contrast to
Figure 7. Targeting the tumor initiating and differentiated populations within DU145 and PC3 carcinoma cell lines by CXCR4
antagonist and conventional therapy. (A) Treatment with CXCR4 antagonist AMD3100 decreases the CD133
+/CD44
+ population but did not
significantly affect the CD133
2/CD44
2 population within prostate cancer cells. The use of cytotoxic drugs alone results in a decrease in proliferating
tumor cells, but leads to an overall increase in the relative population of tumor initiating cells. Combinatorial treatment of PC3 cells with AMD3100
and the conventional chemotherapeutic drug 5-fluouracil decreases both undifferentiated and differentiated cells populations. PC3 cells were grown
in serum-free, EBM medium with supplements and treated with the indicated concentrations of AMD3100 and 5-fluouracil. On the 5
th day the cells
were subjected to flow cytometry analysis; *-p value,0.05. (B) Combinatorial therapy in vivo demonstrates significant inhibition of tumor growth
compared to single drug treatment. The mice were treated with Taxotere (20 mg/kg, 1q.w., p.o) as described (19). Alzet pumps were used to deliver
AMD3100 at a constant rate of 0.25 mg/kg/hour. The pumps loaded with AMD3100 or saline were implanted subcutaneously. The mice were
observed for 8 weeks for appearance and development of tumors. (C) CD133 and CD44 immunostaining on frozen sections of xenograft tumors
treated with combinatorial or mono-therapy from (B) revealed selective inhibition of the CD133
+/CD44
+ population by the CXCR4 antagonist
AMD3100; *-p value,0.05. (D) Western blot analysis showed a significant decrease in FOXO3A phosphorylation in the tumors treated with AMD3100.
doi:10.1371/journal.pone.0031226.g007
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+/CXCR4
2 cells are
just as tumorigenic as CD133
+/CXCR4
+ cells, in prostate tumor
initiating cells CXCR4 expression results in significantly greater
colony formation (Figure 2F) and inhibition of CXCR4 with an
antagonistic antibody reduces tumor growth (Figure 6D). In
addition,ourpreviousworkshowedthatthePI3K/AKT/FOXO3A
axis is a critical regulator of CD44
+/CD133
+ progenitor populations
within prostate cancer cells, and that FOXO3a-dependent gene
expression is inhibited in CD44
+/CD133
+ prostate cancer progen-
itors versus CD44
+/CD133
+ cell population. Our current work
suggests that the CXCL4/CXCR12 signaling pathway may be an
upstream regulator of the PI3K signaling and thus plays multiple
roles in prostate cancer disease progression. Interestingly, we found
that inhibition of PI3K signaling leads to a reduction in CXCR4
expression.Chromatin-IPwithFOXO3Aasatargetshowedadirect
physical interaction between FOXO3A and the CXCR4 promoter.
To our knowledge this is the first report of direct regulation by the
PI3K pathway of CXCR4 expression and thus describes a mutually
positive regulatory feedback loop between the PI3K/AKT and
CXCR4/CXCL12signalingpathwayswhicharebothimportantfor
tumor initiating cell self renewal.
CXCR4 is one of the key regulators of tumor invasiveness and
metastasis development [13], [15], [16], [17], [18], [19], [20], [21],
[22]. BlockingCXCR4receptorfunction bya monoclonal antibody
inhibits cancer cell proliferation, motility and invasion in multiple
preclinical models both in vitro and in vivo [22], [37]. Expression of
CXCR4 is linked to the tendency of prostate cancer cells to
metastasize to the bone, a tissue that expresses a high level of the
chemokine CXCL12 [25], [38]. Our data suggest that CXCL12
regulates the adhesion of CD133
+/CD44
+ prostate cancer
progenitors to the extracellular protein fibrionectin which is
important for distal organ seeding and initiation of secondary
tumors. Moreover, the expression of a5, and b3 integrin subunits,
which form receptors for fibronectin, are strongly upregulated in
CD133
+/CD44
+ DU145 compared to CD133
2/CD44
2 DU145
cells, consistent with a recent study which demonstrated enhanced
expression of a5a n db3 integrins in DU145 cells in response to
activation of the CXCR4/CXCL12 pathway [14]. Fibronectin
receptor aVb3 hasbeenfound to facilitate prostate cancer metastasis
to bone by mediating prostate cancer cell adhesion. It is noteworthy
that aVb3 dependent prostaticcarcinomacellmigrationrequiresthe
activation of focal adhesion kinase and the subsequent activation of
the PI3K/AKT signaling pathway [39], [40].
Taken together, our studies have revealed additional components
of prostate cancer stem cell signaling (Figure S3). CXCL12 is an
important input in CXCR4
+ prostate tumor initiating cells and
leads to an elevated activation of the PI3K pathway and more
robust proliferation of prostate cancer progenitors. Increased
CXCR4expression alsoleadstogreaterintegrin-mediatedadhesion
of cells to extracellular matrix substrates. These findings suggest that
inhibition of the CXCR4/CXCL12 pathway in prostate cancer
progenitors could lead to more effective cancer treatment and may
provide synergistic antitumor activity with conventional therapy.
We observed that inhibition of CXCR4 by the small molecule
antagonist AMD3100 or blockage of CXCR4/CXCL12 interac-
tion by a neutralizing anti-CXCR4 antibody could specifically
inhibits proliferation of prostate progenitor population in PC3 and
DU145 prostate cancer cell lines in vitro and in vivo and may provide
a new approach to deplete prostate cancer stem cells. Other
experiments have also shown that CXCR4 antagonist CTCE-9908
reduced growth of prostate xenografts via inhibition of angiogenesis
and lymphangiogenesis, and induction of apoptosis [41].
In summary, our studies showed that similar to leukemia and
breast cancer, several progenitor cell-like subpopulations can exist
in prostate cancer [42], [43], [44]. Cancer stem cells are likely
hierarchical populations playing different roles in cancer initiation
and progression (Figure S4). CD133
+/CD44
+/CXCR4
+ cells
represent a highly tumorigenic subset of cancer progenitors and
targeting CXCR4 signaling may be beneficial in eliminating this
subpopulation.
Materials and Methods
Cells, reagents and animals
DU145 and PC3 prostate cancer cell lines were obtained from
the ATCC and cultured in the recommended medium containing
10% FBS. NOD.CB17-Prkdc (SCID) mice were obtained from
Jackson Laboratories and maintained under standard conditions
according to institutional guidelines. All surgery was performed
under sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering. The antibodies used were:anti-CXCR4
(ab2074 (Abcam) and MAB172 (R&D Systems)); anti-b-actin
(mAb, Sigma); anti-CD133 (directly conjugated with phycoery-
thrin (PE), clone 293C3, Miltenyi Biotech Ltd); anti-CD44v6
(directly conjugated with allophycocyanin (APC), clone C44-26,
BD Pharmingen); anti-Cytokeratin 5 (clone RCK103, Santa-
Cruz),anti-Cytokeratin 18 (clone E431-1, Epitomics), donkey anti-
rabbit and sheep anti-mouse IgG, HRP-linked whole Ab(GE
Healthcare). CXCR4 antagonist AMD3100 was purchased from
Sigma Aldrich (St. Louis, MO). Taxotere was purchased from LC
Laboratories (Woburn, MA).
Colony formation assay
Cells were plated in 12 well plates at 500 or 1000 cells per well
in triplicate and grown in medium containing 10% FBS for 10
days. The cell were fixed with 10% formalin for 30 min and
stained with 0.05% crystal violet in distilled water for 30 min, then
washed twice with distilled water and air dried.
Sphere formation assay
Single cells were plated at 100, 500 or 1000 cells/mL per well in
triplicates in 24 well low-attachment plates with ultra-low
attachment surface (Fisher Scientific Co., Pittsburgh, PA). Cells
were grown in serum-free Epithelial Basal Medium (EBM, with
bicarbonate and phenol red; Cambrex) supplemented with 4 mg/
mL insulin (Sigma), B27, 20 ng/mL epidermal growth factor
EGF, 20 ng/mL basic fibroblast growth factor FGF (Invitrogen,
Carlsbad, CA). Spheres were analyzed after 7 to 14 days.
Attachment assay
384 well black clear bottom plates (Greiner Bio-One) were
coated with fibronectin (diluted to 50 mg/ml in PBS, Sigma)
overnight. Plates were washed with 1% bovine serum albumin
(BSA) in PBS to block nonspecific cell adhesion. DU145 cells were
plated at a density of 100 cells per well in serum-free Epithelial
Basal Medium (EBM, with bicarbonate and phenol red; Cambrex)
supplemented with 4 mg/mL insulin (Sigma), B27, 20 ng/mL
epidermal growth factor EGF, 20 ng/mL basic fibroblast growth
factor FGF (Invitrogen, Carlsbad, CA). The cells were allowed to
adhere for 1 h. Subsequently, the cells were fixed with 3.7%
formaldehyde in PBS. Non-adherent cells were washed off and the
remaining cells were counted with a microscope.
Flow cytometry analysis of CXCR4, CD44 and CD133
expression
For flow cytometry, cells were dissociated with Accutase
(Innovative Cell Tech Inc., San Diego, CA, USA) and washed 2
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2+ and Mg
2+-free PBS with
1 mM ethylenediaminetetraacetic acid (EDTA), 25 mM Hepes
(pH 7.0) (Gibco BRL), and 1% FBS. Cells were stained live in
staining solution containing conjugated anti-CD44 and anti-
CD133 antibody for 50 min at 4uC. For CXCR4 staining, the
cells were incubated with unconjugated anti-CXCR4 antibody
(MAB172; R&D Systems) followed by staining with anti-mouse
secondary antibody conjugated with Alexa 488. Samples were
analyzed on a BD LSR II flow cytometer (Beckton Dickinson
Immunocytometry Systems, San Jose, CA). A minimum of
500,000 viable cell events were collected per sample. For sorting,
2610
7 cells were processed for CD44 and CD133 multi-color
staining along with appropriate negative controls and single color
positive controls. The CD44
+/CD133
+ and CD44
2/CD133
2
populations were sorted on a BD FACS Diva cell sorter (Beckton
Dickinson Immunocytometry Systems, San Jose, CA).
Histology and immunofluorescence
For cryosectioning, the tumors were fixed by immersion in 4%
paraformaldehyde, cryoprotected in 20% sucrose, frozen, and
embedded in sucrose:OCT (1:1). Cryostat sections (12 mm) were
collected on Superfrost plus slides. Slides were preincubated
30 min in antibody buffer (50 mM NaCl, 50 mM Tris Base, 1%
BSA, 100 mM L-Lysine, 0.04% sodium azide [pH 7.4]) contain-
ing 0.4% Triton and 10% serum and then incubated overnight at
4uC with the primary antibodies anti-CD133 (Abcam, ab27699,
dilution 1:200) and anti-CD44 (Abcam, ab24504, dilution 1:100).
Bound antibodies were detected with appropriate secondary
antibodies conjugated with Alexa 488 or 555 (1:1000; Molecular
Probes) diluted in antibody buffer at room temperature for 1 h.
For CD133 detection, sections were incubated with a goat anti-
mouse biotinylated secondary antibody (1:400; Jackson Immunor-
esearch) followed by incubation with Avidin-Biotin Complex (ABC
elite; Vector laboratories) for 30 min. The slides were then
incubated with Streptavidin-FITC (Vector Laboratories). For
quantification, cells in at least four randomly selected fields of
view were counted for each condition. At least 1000 cells per
condition were counted. For immunofluorescent microscopy,
DU145 cells were plated in a 384 well black clear bottom plate
(Greiner Bio-One) at a density of 100 cells/well in medium
containing 10% serum. After 7 days, the cells were fixed for
30 min in 3.7% formaldehyde at room temperature and
permeabilized with 0.125% Triton X-100 for 10 min. The cells
were washed with PBS, and blocked by incubation with 10% BSA
in PBS. The cells were then incubated with primary antibody
diluted in 3% BSA in PBS (anti-Cytokeratin 5 (clone RCK103,
Santa-Cruz, dilution 1/50) and anti-Cytokeratin 18 (clone E431-1,
Epitomics, dilution 1/100) for 1 h and washed ten times with PBS.
Cells were then incubated for 1 h with a secondary antibody
conjugated with Alexa 488 or 555 (Invitrogen) diluted 1/500 in
3% BSA in PBS. After extensive washes with PBS the cells were
stained with DAPI and examined under epifluorescent illumina-
tion. For quantification, 100 to 300 cells per condition were
counted. For paraffin sectioning, tumor tissues were fixed in 10%
Neutral Buffered Formalin (NBF). After 48 hour the tissues were
processed with a mouse tissue processing cycle and then embedded
in paraffin. Every 10
th slide was stained with Mayer’s Hematoxylin
and Eosin; the adjacent slides were stained with anti-CD133 and
anti-CXCR4 antibodies. Immunohistochemistry was performed
on a Ventana Discover XT. The slides were blocked with avidin/
biotin and stained with anti-CD133 antibody for 1 hour (Abcam,
ab19898 dilution 1:100) with using Ventana CC1 HIER followed
by incubation with biotinylated goat anti-rabbit antibody (Jackson
ImmunoResearch) and labeled using a Ventana DABMap kit.
Alternatively, the slides were blocked with Ventana antibody block
and stained with anti-CXCR4 antibody for 12 hours (Abcam,
ab2074, dilution 1:50) using Ventana CC2 HIER followed by
incubation with Ventana’s Umap anti-rabbit HRP conjugated
antibody and Chromo Dab map detection kit.
In vivo tumorigenicity assay
Protocol 08-223 was approved by the Institutional Animal Care
and Use Committee of the Genomics Institute of the Novartis
Research Foundation. DU145 xenograft tumors were established
using early-passage cells and maintained in NOD.CB17-Prkdc
(SCID) mice. For subcutaneous tumor development 100 mlo f
collagen-embedded cells were injected s.c. into 5–8 week old
NOD.CB17-Prkdc (SCID) mice. Treatment began when tumors
were 100 mm
3 in size. The mice were treated with Taxotere
(20 mg/kg, 1q.w., p.o) as described (12). To ensure consistent
levels of the antagonist throughout the 4 week experimental
period, we used osmotic Alzet pumps (Alza Corporation, Palo
Alto, CA) to deliver AMD3100 at a constant rate of 0.25 mg/kg/
hour. The pumps loaded with AMD3100 or saline were implanted
subcutaneously. The mice were observed for 8 weeks for
appearance and development of tumors.
Microarray analysis
Microarray analysis was carried out as described earlier (5).
Briefly, total RNA was isolated from cell pellets using the RNeasy
kit (Qiagen, Valencia, CA, USA). Sample preparation for
GeneChip analysis was carried out according to the protocol
detailed by Affymetrix (Santa Clara, CA, USA). Briefly, first and
second cDNA strands were synthesized; double stranded cDNA
was in vitro transcribed using the Affymetrix 39 amplification kit;
and the resulting cRNA was purified, fragmented and hybridized
to oligonucleotide arrays (Human Genome U133 Plus 2.0 Array,
catalog number 900467, www.Affymetrix.com) representing over
47,000 transcripts. Arrays were processed using standard Affyme-
trix protocols. The Affymetrix Hybridization Control Kit and
Poly-A RNA control kit were used for hybridization. Probe values
from CEL files were condensed to probe sets using the gcRMA
package from Bioconductor (www.bioconductor.org) and the R
program (R Development Core Team (2004). R: A language and
environment for statistical computing. R Foundation for Statistical
Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://
www.R-project.org). The dataset was unlogged and median scaled
to a target intensity of 100. Primer sets used for microarray
validation shown in Table S1. Data deposition: all data is MIAME
compliant and that the raw data has been deposited in the Gene
Expression Omnibus (GEO) database, www.ncbi.nlm.nih.gov/geo
(accession no. GSE10832).
Chromatin Immunoprecipitation Assay (ChIP)
DU145 cells were stably transfected with FOXO3A-GFP or
control GFP expressing vectors, as described previously (5). ChIP
assays were performed according to the manufacturer’s protocol
(Magna ChIP kit, Millipore). In brief, 7610
6 or 1610
7 cells were
fixed by directly adding formaldehyde (37% stock, Sigma) to the
medium to a final concentration of 1%. After 10 min, 2 M glycine
stock was added (final concentration of 0.125 M glycine, room
temperature, 5 min incubation, gentle mixing) to stop cross-
linking. The cells were washed with PBS twice and collected using
a cell scraper. After centrifugation, cells were resuspended in
swelling buffer (0.1 M Tris pH 7.6, 10 mM KOAc and 15 mM
MgOAc) for 20 min. The nuclei were released using a Dounce
homogenizer (16 strokes). The pellets were collected, lysed, and
the nuclear extracts were subjected to sonication on ice with a
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cipitation was performed overnight at 4uC using 2.5 mgo f
antibody (Anti-FOXO3A/FKHRL1, Millipore). Immunoprecipi-
tated chromatin was extracted using a chromatin IP DNA
purification kit (Active Motif). Primer sets used for PCR of
CXCR4 promoter region shown in Table S1.
Statistical analysis
The results of soft agar colony formation assays, flow cytometry
analysis, cell proliferation assays, and in vivo tumorigenicity assays
were analyzed by paired t-test. A p value of ,0.05 was regarded as
statistically significant
Supporting Information
Figure S1 PC3 CXCR4
+ cells have a higher tumorigenic
potential in vivo as compared to PC3 CXCR4
2 cells. (A)
Secondary spheres formation assay showed the self-renewal
capacity of CXCR4
+ PC3 cells. The primary spheres were
dissociated and single cells were plated at 500 or 1000 cells/mL
per well in triplicate in 24 well low-attachment plates and grown
under sphere forming conditions for 7 days. (B) Adenovirus-
mediated overexpression of CXCR4 in prostate cancer cells
resulted in a more than 2.5-fold increase of CD44
+/CD133
+
population. DU145 cells were infected with adenovirus encoding
CXCR4 under the control of the tet-off regulatory system, and
with control adenovirus and analyzed by flow cytometry 4 days
after infection. For CXCR4 staining, the cells were incubated with
unconjugated anti-CXCR4 antibody (MAB172; R&D Systems)
followed by staining with anti-mouse secondary antibody conju-
gated with Alexa 488. (C) 10
3 CXCR4
+ and CXCR4
2 PC3 cells
collected by FACS sorting were embedded in BD matrigel and
injected s.c. into NOD/SCID mice. *-p value,0.05.
(TIF)
Figure S2 Targeting the tumor initiating population
within DU145 and PC3 carcinoma cell lines by CXCR4
antagonist. (A) Treatment with CXCR4 antagonist AMD3100
decreases the CD133
+/CD44
+ population. PC3 cells were grown
in serum-free, EBM medium with supplements and treated with
0.5 mM AMD3100. On the 5
th day the cells were subjected to flow
cytometry analysis. (B) CD133 and CD44 immunostaining on
frozen sections of xenograft tumors treated with combinatorial or
mono-therapy revealed selective inhibition of the CD133
+/CD44
+
population by the CXCR4 antagonist AMD3100.
(TIF)
Figure S3 Mechanism of CXCR4/CXCL12 dependent
maintenance of prostate cancer progenitors. CXCL4/
CXCR12 – induced transactivation of receptor tyrosine kinases
(EGFR, HER2, IGF-1R, FGFR, etc.) contributes to enhanced
invasive signals and metastatic growth. The CXCL12-induced
adhesion of prostate cancer progenitors to the extracellular matrix
is mediated by integrins. PI3K pathway is one of the key
mechanisms mediating the function of CXCR4 in prostate tumor
initiating population. Targeting CXCR4 signaling with small
molecule inhibitors may be beneficial in eliminating prostate
cancer stem-like cells.
(TIF)
Figure S4 Model of prostate cancer cell heterogeneity.
CXCR4
+ cells represent a highly tumorigenic subset of cancer
progenitors that could also have migratory properties.
(TIF)
Table S1 List of primers used for RT-PCR and ChIP assay.
(DOC)
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